![]() Update statistical approaches to generate larger clinical effect sizes Improve product convenience to cut development costs and expand marketsĤ. For biologics, focus more on cutting cell-line and process development costsĢ. They identified 4 new potential levers to improve biotech industry productivity:ġ. You may remember the impressive paper from Kelvin Stott in 2017 for Endpoints News.Īleks Engel, Brian Finrow and Srini Akkaraju took up the exercise and continued it in the light of new data. Pharma Broken Business Model: An Industry on the Brink of Terminal Decline (2023 Update) During the AAN, the capacity to produce high precision real-world algorithms for treatment evaluation, and predictive analytics to optimize the timing of intake of the treatment will be discussed based on Healint's data " " The collaboration aims to support the development of a new category of PSPs, DTx and studies thanks to the connectivity of Aptar's drug delivery devices, Aptar’s SaMD and DTx Framework, coupled with Healint's capacity to serve millions of patients in neurology for both data-capture and high-speed delivery of digital solutions to those patients and their specialist health care providers. Of course, the possibility to build solutions directly connected to the injectable and nasal devices is also exciting. WHILE keeping the patient focus we all need to see promoted in all specialties. Together, Healint and Aptar Digital cover the digitization of treatments, from the First in patient studies to the FDA validated Digital programs solutions. We are still a healthcare company, nothing to do with the containers in the background :)Īhead of the American Academy of Neurology Congress, we are delighted to announce this first-of-its-kind partnership with Aptar Digital! NB: Photo was taken from our Singapore office roof-top. The team will miss (on the photo) joined us more recently and will be your first contact if you wished to join us in our mission to improve brain health and immune health! Most of the key architects of this change are in this photo! ![]() And last but not least: productization of DTx delivery & virtual studies used and validated by the top 10 big-Pharma in CNS and immunology. It became the number 3 medical subscription app in the US) Our Migraine Buddy app and platform are now flying by themselves, thanks to a 200% growth of users subscriptions. A dozen new clinical studies delivered and are ongoing in North America and Japan, both with industry and academics.įrom AI diagnostic evaluation to Classic Phase II Treatment efficacy in GCP trials We can now invest more than ever in growth and R&D Record revenues! Soon 10 figures LEFT of the comma. 2 years ago, in the midth of the COVID, we were facing challenges with a key client and huge opportunities for our now mature virtual studies and came on board to work on this opportunity. ![]()
0 Comments
Leave a Reply. |